Prostate News and Research

RSS

Scientists create first 3-D image of key protein involved in development of cancers

Scientists from New Zealand and Australia have created the first three-dimensional image of a key protein involved in the development of blood and other cancers.

9 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

New book suggests ways to reduce medical reversals

Medical reversal—when accepted medical interventions are abandoned because they are found to be ineffective—is the "most important problem in medicine today," according to the authors of a new book: Ending Medical Reversal.

8 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

Texas Center for Proton Therapy lures top proton talent as Dallas center nears opening

Texas Center for Proton Therapy has announced the hiring of three dedicated radiation oncologists with experience in radiation oncology and proton beam cancer treatment, completing the center’s key medical staff.

7 Oct 2015

Recipients of 2015 Ferring Innovation Grants announced

Ferring Research Institute Inc. today announced the recipients of the 2015 Ferring Innovation Grants. This global program awards each recipient $50,000 to support research in the fields of Reproductive Health, Gastroenterology and/or Urology.

7 Oct 2015

Researchers study effect of immune tolerance on certain cancer risks

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. "But we didn't know whether this is a consequence of an aggressive tumor or rather its cause," says Rudolf Kaaks, epidemiologist at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Binghamton University biochemist finds new way to fight cancer

A Binghamton University biochemist has discovered a new way to fight cancer, one that attacks only the cancer cells and promises fewer side effects. He hunts hedgehogs.

7 Oct 2015

New online Smart Map shows progress in UK lung cancer care

Roy Castle Lung Cancer Foundation (RCLCF) today launches a new online Smart Map that shows how standards of lung cancer care vary throughout the UK.(1) The resource, available at http://www.roycastle.org/how-we-help/our-campaigns/improving-treatment-and-care/interactive-map, is based on the latest research by the National Lung Cancer Audit (NLCA), published in December 2014.2 This shows encouraging improvements have been made in standards of lung cancer care across multiple UK regions.

7 Oct 2015

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

6 Oct 2015

Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

A recent publication, which received sustained media attention, claimed that most cancers are just “bad luck”. Its authors stated that only about one-third of cancer mutations are caused by known lifestyle or environmental factors.

6 Oct 2015

Novel technique may help women and their oncologists choose options for treating breast cancer

Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk. In contrast, obesity, alcohol abuse, and smoking show a negative association with the disease.

30 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

Although prostate cancer may exhibit no symptoms in its early stages, symptoms like severe or unexplained pain, difficulty walking or climbing stairs, difficulty sleeping or loss of bladder control may emerge when the disease advances as a signal to men to take action with their doctors.

29 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

29 Sep 2015

Collaborative program aims at reducing cancer burden among Hispanic/Latinos receives grant from NCI

A collaborative program aimed at reducing the burden of cancer among Hispanic/Latinos in San Diego and Imperial counties through research and community outreach has received a $13 million grant from the National Cancer Institute, part of the National Institutes of Health. The five-year grant renews funding for a partnership started in 2008 between San Diego State University and Moores Cancer Center at UC San Diego Health.

29 Sep 2015

Prostate News and Research

Scientists create first 3-D image of key protein involved in development of cancers

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

New book suggests ways to reduce medical reversals

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Texas Center for Proton Therapy lures top proton talent as Dallas center nears opening

Recipients of 2015 Ferring Innovation Grants announced

Researchers study effect of immune tolerance on certain cancer risks

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Binghamton University biochemist finds new way to fight cancer

New online Smart Map shows progress in UK lung cancer care

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

Novel technique may help women and their oncologists choose options for treating breast cancer

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New global educational initiative helps men identify symptoms of advanced prostate cancer

New global educational initiative helps men identify symptoms of advanced prostate cancer

Collaborative program aims at reducing cancer burden among Hispanic/Latinos receives grant from NCI

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News